{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:51:11Z","timestamp":1786985471597,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","brainanddevelopment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.braindev.2015.11.007","type":"journal-article","created":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T16:58:45Z","timestamp":1452963525000},"page":"439-448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome"],"prefix":"10.1016","volume":"38","author":[{"given":"Michael R.","family":"Pranzatelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D.","family":"Tate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2015.11.007_b0005","series-title":"(Clinics in Developmental Medicine No. 184-185) Inflammatory and Autoimmune Disorders of the Nervous System in Children. Chapter 10","first-page":"152","article-title":"Opsoclonus-myoclonus syndrome","author":"Pranzatelli","year":"2010"},{"key":"10.1016\/j.braindev.2015.11.007_b0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/jnnp.25.3.271","article-title":"Myoclonic encephalopathy of infants","volume":"25","author":"Kinsbourne","year":"1962","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.braindev.2015.11.007_b0015","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/B978-0-444-52910-7.00042-8","article-title":"Opsoclonus-myoclonus syndrome","volume":"112","author":"Pike","year":"2013","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.braindev.2015.11.007_b0020","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1177\/0883073814549581","article-title":"Effect of increased immunosuppression on developmental outcome of opsoclonus myoclonus syndrome (OMS)","volume":"30","author":"Mitchell","year":"2015","journal-title":"J Child Neurol"},{"key":"10.1016\/j.braindev.2015.11.007_b0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/1043454204272560","article-title":"Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome","volume":"22","author":"Tate","year":"2005","journal-title":"J Pediatr Oncol Nurs"},{"key":"10.1016\/j.braindev.2015.11.007_b0030","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00002826-200111000-00007","article-title":"Controlled pilot study of piracetam for pediatric opsoclonus-myoclonus","volume":"24","author":"Pranzatelli","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.braindev.2015.11.007_b0035","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.62.9.1526","article-title":"B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes","volume":"62","author":"Pranzatelli","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2015.11.007_b0040","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1542\/peds.2010-3114","article-title":"Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life","volume":"128","author":"Brunklaus","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.braindev.2015.11.007_b0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0887-8994(95)00083-R","article-title":"Outcome of children with opsoclonus-myoclonus regardless of etiology","volume":"13","author":"Hammer","year":"1995","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.braindev.2015.11.007_b0050","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0022-3476(06)80167-8","article-title":"Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma","volume":"125","author":"Koh","year":"1994","journal-title":"J Pediatr"},{"key":"10.1016\/j.braindev.2015.11.007_b0055","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF01953945","article-title":"Neurological sequelae of the dancing eye syndrome","volume":"155","author":"Pohl","year":"1996","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.braindev.2015.11.007_b0060","unstructured":"Tate ED, McGee NM, Pranzatelli MR. Clinical and demographic features of 389 children with OMS: an International Cohort. In: Proceedings of the 13th International Child Neurology Congress, Iguazu Falls, Brazil, May 4\u20139, 2014. JICNA 1(Suppl. 1):27 (FP79), 2014."},{"key":"10.1016\/j.braindev.2015.11.007_b0065","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/mds.10283","article-title":"Forty-one year follow-up of childhood-onset opsoclonus-myoclonus-ataxia: cerebellar atrophy, multiphasic relapses, response to IVIG","volume":"17","author":"Pranzatelli","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.braindev.2015.11.007_b0070","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.20573","article-title":"Epstein\u2013Barr virus related opsoclonus-myoclonus-ataxia does not rule out the presence of occult neuroblastic tumors","volume":"47","author":"Cardesa-Salzmann","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.braindev.2015.11.007_b0075","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.2174\/138161212802502323","article-title":"Paraneoplastic neurological syndromes\u2014diagnosis and management","volume":"18","author":"Blaes","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.braindev.2015.11.007_b0080","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.braindev.2011.04.005","article-title":"Another promising treatment option for neuroblastoma-associated opsoclonus-myoclonus syndrome by oral high-dose dexamethasone pulse: lymphocyte markers as disease activity","volume":"34","author":"Oguma","year":"2012","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2015.11.007_b0085","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jneuroim.2011.12.014","article-title":"Key role of CXCL13\/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS","volume":"243","author":"Pranzatelli","year":"2012","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.braindev.2015.11.007_b0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1742-2094-10-10","article-title":"BAFF\/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy","volume":"10","author":"Pranzatelli","year":"2013","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.braindev.2015.11.007_b0095","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pediatrneurol.2011.02.012","article-title":"Cerebrospinal fluid oligoclonal bands in childhood opsoclonus-myoclonus","volume":"45","author":"Pranzatelli","year":"2011","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.braindev.2015.11.007_b0100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1189\/jlb.0213106","article-title":"Role of BAFF in opsoclonus-myoclonus syndrome, a bridge between cancer and autoimmunity","volume":"94","author":"Raffaghello","year":"2013","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.braindev.2015.11.007_b0105","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0887-8994(02)00457-5","article-title":"Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia","volume":"27","author":"Pranzatelli","year":"2002","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.braindev.2015.11.007_b0110","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1469-8749.2011.03997.x","article-title":"Going with the flow: neuroinflammation","volume":"53","author":"Pranzatelli","year":"2011","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.braindev.2015.11.007_b0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756285614560733","article-title":"Towards the implementation of \u2018no evidence of disease activity\u2019 in multiple sclerosis treatment: the multiple sclerosis decision model","volume":"8","author":"Stangel","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.braindev.2015.11.007_b0120","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.pediatrneurol.2005.05.018","article-title":"Delayed, recurrent opsoclonus-myoclonus syndrome responding to plasmapheresis","volume":"33","author":"Armstrong","year":"2005","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.braindev.2015.11.007_b0125","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1176\/jnp.2006.18.2.239","article-title":"Mood and behavioral dysfunction with opsoclonus-myoclonus ataxia","volume":"18","author":"Turkel","year":"2006","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.braindev.2015.11.007_b0130","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1542\/peds.2004-2377","article-title":"Longitudinal neurodevelopmental evaluation of children with opsoclonus-ataxia","volume":"116","author":"Mitchell","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.braindev.2015.11.007_b0135","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-0029-1237723","article-title":"Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome","volume":"40","author":"De Grandis","year":"2009","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.braindev.2015.11.007_b0140","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/dmcn.12594","article-title":"Cerebellar and cortical abnormalities in paediatric opsoclonus-myoclonus syndrome","volume":"57","author":"Anand","year":"2015","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.braindev.2015.11.007_b0145","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/mds.23084","article-title":"Electrophysiological evidence of cerebral dysfunction in childhood opsoclonus-myoclonus syndrome","volume":"25","author":"Sakuma","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.braindev.2015.11.007_b0150","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jpeds.2005.05.016","article-title":"Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone","volume":"147","author":"Pranzatelli","year":"2005","journal-title":"J Pediatr"},{"key":"10.1016\/j.braindev.2015.11.007_b0155","first-page":"1","article-title":"Center for Disease Control and Prevention. General Recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"Kroger","year":"2011","journal-title":"MMWR"},{"key":"10.1016\/j.braindev.2015.11.007_b0160","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1097\/MPH.0b013e3181cf0726","article-title":"Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome","volume":"32","author":"Pranzatelli","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.braindev.2015.11.007_b0165","unstructured":"Rituxan (Genentech, Inc.): FDA Package Insert and Label Information. <http:\/\/druginserts.com\/lib\/rx\/meds\/rituxan-1\/>."},{"key":"10.1016\/j.braindev.2015.11.007_b0170","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/qjmed\/hcu094","article-title":"Hypogammaglobulinaemia after rituximab treatment\u2014incidence and outcomes","volume":"107","author":"Makatsori","year":"2014","journal-title":"Q J M"},{"key":"10.1016\/j.braindev.2015.11.007_b0175","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.coi.2015.01.018","article-title":"B cells take the front seat: dysregulated B cell signals orchestrate loss of tolerance and autoantibody production","volume":"33","author":"Jackson","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.braindev.2015.11.007_b0180","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease","volume":"83","author":"Dale","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2015.11.007_b0185","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.pediatrneurol.2008.05.015","article-title":"Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome","volume":"39","author":"Leen","year":"2008","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.braindev.2015.11.007_b0190","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejpn.2007.05.005","article-title":"Chronic relapsing opsoclonus-myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses","volume":"12","author":"Wilken","year":"2008","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.braindev.2015.11.007_b0195","doi-asserted-by":"crossref","first-page":"E163","DOI":"10.1002\/pbc.24646","article-title":"Ofatumumab for refractory opsoclonus-myoclonus syndrome following neuroblastoma","volume":"60","author":"Ketterl","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.braindev.2015.11.007_b0200","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/0883073808324217","article-title":"Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil","volume":"24","author":"Pranzatelli","year":"2009","journal-title":"J Child Neurol"},{"key":"10.1016\/j.braindev.2015.11.007_b0205","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejpn.2011.05.013","article-title":"Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments","volume":"16","author":"Battaglia","year":"2012","journal-title":"Eur J Paediatr Neurol"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760415002375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760415002375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T00:28:13Z","timestamp":1537057693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760415002375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0387760415002375"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2015.11.007","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2015.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}